Bristol-Myers Squibb buy stratec
Start price
19.04.18
/
50%
€47.22
Target price
04.11.21
€62.00
Performance (%)
8.26%
End price
05.11.21
€51.12
Summary
This prediction ended on 05.11.21 with a price of €51.12. The BUY prediction by stratec finished with a performance of 8.26%. A total of €5.66 was paid as dividends for this prediction. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Bristol-Myers Squibb | -3.671% | -3.671% | -22.759% | -18.263% |
| iShares Core DAX® | -2.385% | 3.986% | 16.836% | 16.377% |
| iShares Nasdaq 100 | -4.527% | -0.258% | 18.824% | 29.987% |
| iShares Nikkei 225® | -4.129% | 4.382% | 10.912% | -1.507% |
| iShares S&P 500 | -2.885% | 1.387% | 20.391% | 35.258% |
Comments by stratec for this prediction
In the thread Bristol-Myers Squibb diskutieren
stratec stimmt dem Sentiment von 'Buy' zu
stratec stimmt am 19.04.2018 dem Buy-Gesamtsentiment mit dem Kursziel 64.9$ zu.
Tuesday, October 22, 2019
A Phase 3 clinical trial, CheckMate-9LA, evaluating Bristol-Myers Squibb's (NYSE:BMY) Opdivo (nivolumab) + low-dose Yervoy (ipilimumab), together with two cycles of chemo, for the first-line treatment of advanced non-small cell lung cancer (NSCLC) met the primary endpoint of overall survival (OS) compared to chemo alone for up to four cycles followed by optional maintenance therapy.
Kursziel geändert auf 62,0
In the thread Trading Bristol-Myers Squibb
Die von stratec gewählte maximale Laufzeit wurde überschritten